Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| CynosureLutronic | INDUSTRY |
Not provided
Not provided
Not provided
There are 3 main objectives of this proposal as follows: (1) to assess the efficacy of radiofrequency microneedling in the treatment of erythematotelangiectatic and or papulopustular rosacea, (2) to determine the potential for combination treatment of radiofrequency microneedling with the 532 nm KTP laser, and (3) identify potential novel therapeutic strategies for the treatment of rosacea.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Potassium titanyl phosphate (KTP) Laser Therapy with unilateral Radiofrequency Microneedling | Experimental | Participants will be in this group for up to 36 weeks |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| KTP Laser Therapy | Device | Participants will receive full face treatments with 532 nm KTP laser for 3 sessions at 8-12 weeks apart. Laser therapy will be conducted in person. Each laser treatment session will last up to 10 minutes. |
| Measure | Description | Time Frame |
|---|---|---|
| Change in Rosacea severity measured by the Clinician's Erythema Assessment (CEA) | Score range from 0 (clear skin) to 4 (severe erythema). Lower scores indicate less rosacea severity as assessed by the CEA scale. | Baseline, up to 16 weeks after the last treatment |
| Measure | Description | Time Frame |
|---|---|---|
| Change in Patient reported impact on quality of life (QOL) measured by DLQI | Dermatology Quality of Life Index (DLQI) is a validated 10-item questionnaire assessing the impact of dermatological conditions on a patient's QOL, with scores ranging from 0 (no impact) to 30 (extremely large impact). Higher scores indicate higher impact on QOL. | Baseline, up to 16 weeks after the last treatment |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Maria Muniz Muniz | Contact | 305-689-2646 | mmuniz@med.miami.edu |
| Name | Affiliation | Role |
|---|---|---|
| Ariel Eber, MD | University of Miami | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Miami Dermatology Miami Beach Clinic | Recruiting | Miami Beach | Florida | 33128 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D012393 | Rosacea |
| ID | Term |
|---|---|
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Radiofrequency microneedling | Device | Participants will receive unilateral facial treatments with radiofrequency microneedling device for 3 sessions at 8-12 weeks apart. Radiofrequency microneedling will be conducted in person. Each treatment session will last up to 1 hour. |
|
| Change in patient satisfaction with treatment outcomes measured by Patient Self-Assessment (PSA) | The PSA scale measures the patient's subjective satisfaction with skin's appearance on a scale of 0 (clear of unwanted redness) to 4 (completely unacceptable redness). Higher scores indicate less satisfaction. | Baseline, up to 16 weeks after the last treatment |
| Change in Global Aesthetic Improvement scale (GAIS) | The GAIS scores range from 1 (very much improved) to 5 (the appearance is worse than the original condition). Higher scores indicate less satisfaction. | Baseline, up to 16 weeks after the last treatment |
| Proportion of blinded photo assessment | Proportion of identification of before and after photos by three blinded rosacea experts will be reported. Expert identification greater than or equal to 80% or greater will be reported. | Baseline, up to 16 weeks after the last treatment |